CDT Equity Inc.

CDT Equity Inc. noted Sarborg Limited's recent fundraise from a New York-based private investment fund, which implies a fully diluted valuation of approximately $638.3 million for Sarborg. Based on this, CDT's 1,020 shares in Sarborg are now valued at $127.5 million. The proceeds from the fundraise will support the launch of SarborgQ, Sarborg's new quantum computing division, and further development of its AI platform. CDT views this as validation of Sarborg's business model and expects to benefit from its continued growth.

CDT Equity Inc. announced a significant debt restructuring, repaying over $6.3 million in legacy financing obligations from Alliance Global Partners and Ascent Partners. This move simplifies the company's capital structure and materially strengthens its balance sheet. Concurrently, CDT entered into a new Loan Agreement with JJ Astor for up to $1,460,000 to support working capital, with an initial tranche of approximately $268,000 already funded. The company's CEO highlighted a total debt reduction of over $4 million since early 2025, positioning CDT for strategic execution and long-term shareholder value creation.

CDT Equity Inc. announced it received a written notice from Nasdaq on May 21, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. This constitutes non-compliance with Nasdaq's Periodic Filing Requirement, though it does not immediately impact the company's listing or trading. CDT Equity has until July 20, 2026, to submit a plan to regain compliance and anticipates filing the Form 10-Q once its review process is complete.

CDT Equity Inc. has entered into two amendments to its existing financing agreements. Amendment No. 2 to the directed stock purchase agreement (equity line of credit) sets the gross purchase price for regular purchases at $510,000 without the purchaser's consent and extends the adjustment period. Additionally, an amendment to the Senior Secured Convertible Promissory Note allows the company to retain 90% of proceeds from future debt or equity financings, with the remaining 10% allocated to note repayment. Both amendments are temporary, effective only until May 31, 2026.

CDT Equity Inc. announced that Sarborg Limited, in which CDT holds a 20% stake, has filed a new Substance of Matter (SOM) patent covering two established compounds in the cystic fibrosis market. Sarborg developed the patent using its proprietary Signature Agent and Multi-Agent platform, achieving filing in under three weeks. CDT views this as strong validation of Sarborg's platform capabilities and its commercial potential, intending to leverage this approach to expand its intellectual property and explore combination therapies with its own assets.

CDT Equity Inc. announced that AZD5904, a potent Myeloperoxidase inhibitor, has progressed into the Patent Cooperation Treaty (PCT) phase, significantly enhancing its global intellectual property protection. The asset has demonstrated a favorable safety profile across five Phase 1 studies with 181 subjects dosed, and CDT holds existing patents for its use in idiopathic male infertility. Leveraging this robust clinical data and expanded global IP strategy, CDT is now actively seeking out-licensing and strategic partnering opportunities to advance AZD5904 into later-stage development, targeting significant unmet medical needs in infertility markets.

CDT Equity Inc. announced the appointment of Ulrik Olsen as an independent director to its Board, effective April 27, 2026. Mr. Olsen will join the Audit, Compensation, and Nominating and Corporate Governance Committees. Concurrently, Freda Lewis-Hall resigned from the Board due to family health reasons, leading to Chele Chiavacci Farley's appointment as chairperson of the Board and Nominating and Corporate Governance Committee, and Simon Fry's appointment as chairperson of the Audit Committee.

CDT Equity Inc. provided a strategic update, detailing its multi-pathway value creation model. This strategy combines a pharmaceutical asset portfolio, proprietary solid-form intellectual property, and AI-driven indication discovery through its 20% stake in Sarborg Limited. The company aims to generate long-term shareholder value via a capital-efficient out-licensing model. This approach leverages clinically validated assets from AstraZeneca, enhances them with solid-form innovation, and uses AI-informed indication selection to create attractive partnership opportunities.

CDT Equity Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company confirmed its status as a non-accelerated filer, smaller reporting company, and emerging growth company. As of April 15, 2026, there were 4,858,417 shares of common stock outstanding. The filing indicates the company has met all SEC reporting requirements for the past 12 months.